select a format

Single User License
USD 250 INR 16023
Site License
USD 500 INR 32045
Corporate User License
USD 750 INR 48068

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Les Laboratoires Servier SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Les Laboratoires Servier SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH30956D
  • |
  • Pages: 75
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Les Laboratoires ServierSAS (Servier) is a pharmaceutical company that carries out research and development, manufacture and marketing of drugs for the treatment of cardiovascular diseases, central nervous system (CNS) diseases, diabetes, cancer and bone, muscle and joint diseases. The company's portfolio of marketed products covers various diseases including cardiovascular disease, rheumatic problems, venous disease, neurological conditions, cancer and endocrine disorders. It invests substantial amount of revenue in R&D. Servier operates research centers in France and Hungary; and International Centers for Therapeutic Research (ICTRs) across the world. With strong presence in international markets, the company sells its products across the world. Servier is headquartered in Ile-de-France, France.

Les Laboratoires Servier SAS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Les Laboratoires Servier Acquires Rights Of CX1632 From Cortex Pharma Through Exercise Of Option 16

Venture Financing 17

Ilkos Therapeutics Raises USD14 Million in Seed Financing 17

Partnerships 18

Vernalis and Servier Enter into Discovery Agreement 18

Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 19

Daiichi Sankyo Enters into Distribution Agreement with Servier Canada 20

Spectrum Pharma Enters into Agreement with Servier Canada 20

Crossbeta Biosciences Enters into Research Agreement with Servier Labs 21

Vect-Horus Enters into Agreement with Servier 22

Hybrigenics Extends Research Agreement with Les Laboratoires Servier 23

GeNeuro Enters into Co-Development Agreement with Servier for GnbAC-1 24

Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 25

Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 26

Servier Expands Agreement with Novartis 27

Cellectis Enters Into Co-Development Agreement With Servier 28

Institut Curie Extends Research Agreement With Servier To Develop Breast Cancer Treatments 29

Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 30

Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 31

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 32

Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 33

Vernalis And Servier Extend Oncology Drug Discovery Agreement 33

NovAliX And Servier Enter Into Drug Discovery Agreement 34

Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 35

Les Labs Servier Enters Into Research Agreement With Monash Institute 36

Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 37

Les Laboratoires Servier Enters Into Research And Development Agreement With Prognomix 38

Les Laboratoires Enters Into Co-Development Agreement With miRagen Therapeutics 39

Hybrigenics Enters Into Research Agreement With Les Laboratoires Servier 40

Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 41

Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos 42

Intercept Pharma Enters Into Co-Development Agreement With Servier 43

Servier Enters Into Research Collaboration With Singapore Immunology Network 44

Licensing Agreements 45

Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 45

OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 46

Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 47

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 48

Servier Extends Licensing Agreement with miRagen 49

Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 50

Pfizer Enters into Licensing Agreement Servier for UCART19 52

Servier Exercises Option for Licensing Agreement with Cellectis 53

Horizon Discovery Enters into Licensing Agreement with Servier Lab 54

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 55

Taiho Pharma Enters into Licensing Agreement with Servier 55

Servier and miRagen Extend Licensing Agreement for Cardiovascular Disease 56

Celladon Enters Into Option For Licensing Agreement With Servier 57

Servier Exercises Option For Licensing Agreement With MacroGenics For DART Product 58

Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 59

Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 60

Servier Enters Into Licensing Agreement With EOS For Antitumor Drug 61

MacroGenics Enters Into Option For Licensing Agreement With Servier For DART Products 63

BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 64

Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine 65

Asset Transactions 66

XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 66

Acquisition 67

Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 67

Les Laboratoires ServierSAS-Key Competitors 70

Key Employees 71

Locations And Subsidiaries 72

Head Office 72

Other Locations & Subsidiaries 72

Recent Developments 74

Clinical Trials 74

Jun 20, 2016: Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) 74

Appendix 75

Methodology 75

About GlobalData 75

Contact Us 75

Disclaimer 75

List of Figures

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10

List of Tables

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9

Les Laboratoires ServierSAS, Deals By Therapy Area, 2011 to YTD 2017 10

Les Laboratoires ServierSAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Les Laboratoires Servier Acquires Rights Of CX1632 From Cortex Pharma Through Exercise Of Option 16

Ilkos Therapeutics Raises USD14 Million in Seed Financing 17

Vernalis and Servier Enter into Discovery Agreement 18

Les Laboratoires Servier Enters into Research Agreement with Center for Applied Medical Research 19

Daiichi Sankyo Enters into Distribution Agreement with Servier Canada 20

Spectrum Pharma Enters into Agreement with Servier Canada 20

Crossbeta Biosciences Enters into Research Agreement with Servier Labs 21

Vect-Horus Enters into Agreement with Servier 22

Hybrigenics Extends Research Agreement with Les Laboratoires Servier 23

GeNeuro Enters into Co-Development Agreement with Servier for GnbAC-1 24

Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 25

Servier Enters into Research Agreement with Walter and Eliza Hall Institute of Medical Research 26

Servier Expands Agreement with Novartis 27

Cellectis Enters Into Co-Development Agreement With Servier 28

Institut Curie Extends Research Agreement With Servier To Develop Breast Cancer Treatments 29

Servier Enters Into Co-Development Agreement With Xention For XEN-D0103 30

Servier Enters Research Collaboration With Singapore Immunology Network For Anti-Cancer Drugs 31

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 32

Afraxis And Servier Enter Into Agreement To Discover Drugs For CNS Disorders 33

Vernalis And Servier Extend Oncology Drug Discovery Agreement 33

NovAliX And Servier Enter Into Drug Discovery Agreement 34

Servier Enters Into R&D Agreement With Florey Institute of Neuroscience and Mental Health 35

Les Labs Servier Enters Into Research Agreement With Monash Institute 36

Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 37

Les Laboratoires Servier Enters Into Research And Development Agreement With Prognomix 38

Les Laboratoires Enters Into Co-Development Agreement With miRagen Therapeutics 39

Hybrigenics Enters Into Research Agreement With Les Laboratoires Servier 40

Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 41

Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos 42

Intercept Pharma Enters Into Co-Development Agreement With Servier 43

Servier Enters Into Research Collaboration With Singapore Immunology Network 44

Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 45

OSE Immunotherapeutics Enters into Option Licensing Agreement with Les Laboratoires Servier 46

Ilkos Therapeutics Enters into Licensing Agreement with Servier Canada 47

Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 48

Servier Extends Licensing Agreement with miRagen 49

Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 50

Pfizer Enters into Licensing Agreement Servier for UCART19 52

Servier Exercises Option for Licensing Agreement with Cellectis 53

Horizon Discovery Enters into Licensing Agreement with Servier Lab 54

Sumitomo Dainippon Pharma Enters into Licensing Agreement with Servier Lab 55

Taiho Pharma Enters into Licensing Agreement with Servier 55

Servier and miRagen Extend Licensing Agreement for Cardiovascular Disease 56

Celladon Enters Into Option For Licensing Agreement With Servier 57

Servier Exercises Option For Licensing Agreement With MacroGenics For DART Product 58

Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 59

Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 60

Servier Enters Into Licensing Agreement With EOS For Antitumor Drug 61

MacroGenics Enters Into Option For Licensing Agreement With Servier For DART Products 63

BioInvent International Enters Into Licensing Agreement With Les Laboratoires Servier 64

Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine 65

XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 66

Servier Completes Acquisition of Remaining 49.09% Stake in Egis Pharma For USD483 Million 67

Les Laboratoires ServierSAS, Key Competitors 70

Les Laboratoires ServierSAS, Key Employees 71

Les Laboratoires ServierSAS, Subsidiaries 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Les Laboratoires Servier SAS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com